User login
A free continuing education course, FDA Overview of Biosimilar Products, is available to health care providers. The course was designed to help providers strengthen their knowledge and understanding of biosimilars and interchangeable products, which are not the same as generic products.
In February 2015, the FDA approved the first biosimilar in the U.S., and there is growing interest in biosimilars in the pharmaceutical industry. The new course will help health care professionals understand how a biosimilar can be prescribed and dispensed, and how and when an interchangeable product can be substituted for another biological product.
The course is available to health professionals on FDA’s CDERLearn website and can be completed on a tablet for those not at their desktop computer. Click for more information.
A free continuing education course, FDA Overview of Biosimilar Products, is available to health care providers. The course was designed to help providers strengthen their knowledge and understanding of biosimilars and interchangeable products, which are not the same as generic products.
In February 2015, the FDA approved the first biosimilar in the U.S., and there is growing interest in biosimilars in the pharmaceutical industry. The new course will help health care professionals understand how a biosimilar can be prescribed and dispensed, and how and when an interchangeable product can be substituted for another biological product.
The course is available to health professionals on FDA’s CDERLearn website and can be completed on a tablet for those not at their desktop computer. Click for more information.
A free continuing education course, FDA Overview of Biosimilar Products, is available to health care providers. The course was designed to help providers strengthen their knowledge and understanding of biosimilars and interchangeable products, which are not the same as generic products.
In February 2015, the FDA approved the first biosimilar in the U.S., and there is growing interest in biosimilars in the pharmaceutical industry. The new course will help health care professionals understand how a biosimilar can be prescribed and dispensed, and how and when an interchangeable product can be substituted for another biological product.
The course is available to health professionals on FDA’s CDERLearn website and can be completed on a tablet for those not at their desktop computer. Click for more information.
